( Wiley-Blackwell ) Psoriatic arthritis affects about 11 percent of patients with psoriasis. Anti-tumor necrosis factor ? (anti-TNF?) agents, which block signaling molecules that induce inflammation, improve the symptoms of psoriatic arthritis. Golimumab is a new human monoclonal antibody that works against TNF? and has been shown to be beneficial within two weeks of the first subcutaneous …
Arthritis Information
